


**Table 3.** Incidences and Hazard Ratios for First Occurrence of Events by Treatment Group

		Celecoxib Naproxen Placebo											
Number with follow-up data		717	713	1,070									
Event	Subcategory (Number of Events)	Events (3-y Incidence) (%) <sup>a</sup>			Celecoxib vs. Placebo			Naproxen vs. Placebo					
		Celecoxib	Naproxen	Placebo	Hazard Ratio	95%CI	p-Value	Hazard Ratio	95%CI	p-Value			
Cardio/cerebrovascular events	MI (34)	8 (1.80)	13 (2.19)	13 (2.01)	0.91	0.38–2.19	0.83	1.49	0.69–3.22	0.31			
	Stroke (24)	7 (1.05)	10 (2.38)	7 (1.23)	1.47	0.52–4.20	0.47	2.13	0.81–5.60	0.12			
	CHF (18)	3 (0.73)	8 (1.51)	7 (0.85)	0.63	0.16–2.44	0.50	1.70	0.62–4.69	0.30			
	TIA (27)	8 (1.55)	9 (2.20)	10 (1.35)	1.08	0.42–2.78	0.87	1.34	0.55–3.31	0.52			
Composite events	CV death/MI (39)	11 (2.41)	13 (2.19)	15 (2.52)	1.08	0.50–2.36	0.84	1.29	0.61–2.72	0.50			
	CV death/MI/stroke (62)	17 (3.26)	23 (4.54)	22 (3.74)	1.14	0.61–2.15	0.68	1.57	0.87–2.81	0.13			
	CV death/MI/stroke/ CHF (79)	20 (4.00)	31 (6.05)	28 (4.46)	1.06	0.60–1.88	0.85	1.66	1.00–2.77	0.05			
	CV death/MI/stroke/ CHF/ TIA (105)	28 (5.54)	40 (8.25)	37 (5.68)	1.10	0.67–1.79	0.72	1.63	1.04–2.55	0.03			
Aspirin	Aspirin use at baseline (45)	14 (8.40)	15 (9.58)	16 (7.55)	1.24	0.60–2.58	0.56	1.40	0.69–2.83	0.35			
	No aspirin use at baseline (60)	14 (4.30)	25 (7.87)	21 (4.87)	0.98	0.50–1.92	0.95	1.81	1.01–3.24	0.04			

Hazard ratios, CIs, and *p*-values were obtained using Cox proportional hazards regression of the first occurrence of events.

<sup>a</sup> 3-y incidence is the percentage of participants experiencing the event by 3 y after randomization, as estimated with the Kaplan-Meier method.

doi:10.1371/journal.pctr.0010033.t003



\*CVD = Cardio/cerebrovascular deaths; MI = myocardial infarction; CHF = congestive heart failure; TIA = transient ischemic attack

**Figure 2.** Graph of Time to Cardiovascular Death, MI, Stroke, CHF, or TIA

doi:10.1371/journal.pctr.0010033.g002